Michiel de Haan
Founder at Aescap Venture Management BV
Michiel de Haan active positions
Companies | Position | Start | End |
---|---|---|---|
Aescap Venture Management BV
Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Founder | 2004-12-31 | - |
Private Equity Investor | 2004-12-31 | - | |
Avantium Technologies BV
Avantium Technologies BV Miscellaneous Commercial ServicesCommercial Services Avantium Technologies BV operates as chemical technology company. It offers a breeding ground for revolutionary renewable chemistry solutions. The firm specializes in innovations and technologies for catalytic research and development services and systems. The company was founded in February 2000 and is headquartered in Amsterdam, the Netherlands | Director/Board Member | - | - |
Career history of Michiel de Haan
Former positions of Michiel de Haan
Companies | Position | Start | End |
---|---|---|---|
AVANTIUM N.V. | Director/Board Member | - | 2017-03-14 |
ProtAffin Biotechnologie AG
ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Director/Board Member | - | 2014-02-16 |
European Venture Philanthropy Association | Founder | - | - |
The European Venture Capital Association | Chairman | - | - |
Training of Michiel de Haan
Erasmus University Rotterdam | Masters Business Admin |
Statistics
International
Netherlands | 5 |
Austria | 2 |
United States | 2 |
Operational
Director/Board Member | 3 |
Founder | 2 |
Private Equity Investor | 1 |
Sectoral
Finance | 2 |
Health Technology | 2 |
Producer Manufacturing | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
AVANTIUM N.V. | Producer Manufacturing |
Private companies | 5 |
---|---|
Aescap Venture Management BV
Aescap Venture Management BV Investment ManagersFinance Aescap Venture Management BV is an independent venture capital investment firm based in Amsterdam. Aescap was founded in 2005 by Michiel de Haan and Dinko Valerio. Inspired by the name of the Greek god of healthcare, Aesculapiu, the firm's name is an acronym for 'Accelerating European Science Companies and Products.' The firm focuses on developing growth in European firms in the biomedical sector. | Finance |
ProtAffin Biotechnologie AG
ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action. | Health Technology |
The European Venture Capital Association | |
Avantium Technologies BV
Avantium Technologies BV Miscellaneous Commercial ServicesCommercial Services Avantium Technologies BV operates as chemical technology company. It offers a breeding ground for revolutionary renewable chemistry solutions. The firm specializes in innovations and technologies for catalytic research and development services and systems. The company was founded in February 2000 and is headquartered in Amsterdam, the Netherlands | Commercial Services |
European Venture Philanthropy Association |
- Stock Market
- Insiders
- Michiel de Haan
- Experience